case_images: PMC10858451_01
case_images: PMC10858451_02
case_images: Brain MRI using contrast agents.
case_images: fneur-14-1324269-g0001.jpg
case_images: PMC10858451_02_fneur-14-1324269-g0001.jpg
case_images: F1
case_images: MRI), which had an expansive character and showed no gadolinium enhancement (Figure 1). Moreover, the lesion was described by the radiologist as heterogenous, hyperintense in T2-weighted and Fluid Attenuated Inversion Recovery sequences, hypointense in T1-weighted sequence and there was no restriction of diffusion observed.
case_images: PMC10858451_03
case_images: 18F-fluorothymidine PET-MRI of the brain.
case_images: fneur-14-1324269-g0002.jpg
case_images: PMC10858451_03_fneur-14-1324269-g0002.jpg
case_images: F2
case_images: The non-MS etiology of the lesion was thus considered. 18F-fluorothymidine PET-MRI did not demonstrate an increased accumulation of radiopharmaceutical within the lesion and there was no post-contrast enhancement of the lesion (Figure 2).
case_images: PMC10858451_04
case_images: PMC10858451_05
case_images: PMC10858451_06
case_images: PMC10858451_07